ABOUT US
关于我们
Nanolattix Group
Nanolattix Group is an overseas core technical team led by Dr. Zhican Qu, a high-level overseas life science talent introduced by the state, responding to the call of Shanxi Province's economic transformation, carrying independent intellectual property biotechnology and start-up capital, and setting up a national high-tech enterprise integrating product research and development, technology output, production and sales. Nanolattix takes life and health as its core, focusing on innovation and technological transformation in the fields of medical medicine and general health. Its business covers biomedicine, medical devices, plant extraction, precision health and other industries. So far, the entrepreneurial team led by Dr. Zhican Qu has declared more than 50 invention patents in the field of biomedicine, insisting on multi-level innovation, rapidly transforming scientific research results, self-making and rolling forward.
Date of Establishment
Authorized patent
Application Areas
In the field of medical medicine, Nanolattix has set up a Bio-Lattix core biotechnology platform, covering three modules of drug target screening, antibody engineering and ADC patent drug research, established more than 10 new drug development pipelines with monoclonal antibody ADC, double antibody ADC and nano antibody ADC, and deployed 7 development pipelines of RDC innovative drugs for precision internal radiotherapy coupled with antibody and radioisotope. Core product T320 anti-cancer drugs, targeting cervical cancer, pancreatic cancer, non-small cell lung cancer and other solid tumors. The drug has obtained the FDA pancreatic cancer ODD (orphan drug) qualification, will fill the national biomedical new target gap, and strive to two to three years of listing, is expected to have more than 10 billion market potential.
In the field of plant extraction precision health, Nanolattix takes the international leading targeted component extraction technology with independent intellectual property rights as the core, and relies on plant resources with Chinese characteristics to build a national plant extraction laboratory, focusing on the field of "precision health, scientific and technological skin beauty. At present, it mainly covers four modules of peony beauty economy transdermal penetration into skin and body-beautifying products, medicine and food homologous efficacy and health care products, medical devices and the development of new multi-target and multi-target plant drugs. It has the production license of makeup number, food number and machinery number, has passed many quality system certifications such as ISO9001, ISO22000, international GMPc and ISO22716, and has a 100000-level medicine clean workshop, A number of advanced production lines have been built, including standardized production lines for skin care products (7), food and drug homologous food production lines (3), standardized production lines for medical devices (2) and standardized production lines for disinfection and hygiene products (2), with an annual production capacity of more than 3 billion, providing comprehensive one-stop services for independent brands, co-construction of brands and ODM/OEM.
Nanolattix will continue to take "curing cancer and maintaining health" as its mission, and "becoming a great pharmaceutical and health company" as its vision, to improve the overall level of the development of China's biopharmaceutical industry, to meet the accessibility of medicines for the people and the people's good life and health The pursuit of wishes is the core goal, continuous innovation, and never stop.
